

Ig-PLP1




FIG. 1A

Ig-PLP-LR




FIG. 1B




FIG. 2A





FIG. 2B








FIG. 4


**FIG. 5A**



**FIG. 5B**



**FIG. 5C**






FIG. 6




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B






FIG. 9A




FIG. 9B




FIG. 10A






FIG. 10B




**FIG. 10C**




**FIG. 10D**


Downloaded from www.sagepub.com at UNIV OF CALIF SDG on June 11, 2015




**FIG. 11**



**FIG. 12**



**FIG. 13A**



**FIG. 13B**





FIG. 13C




(<sup>3</sup>H)-Thymidine incorporation (cpm x 10<sup>-3</sup>)




**FIG. 14A**

(<sup>3</sup>H)-Thymidine incorporation (cpm x 10<sup>-3</sup>)




**FIG. 14B**

(<sup>3</sup>H)-Thymidine incorporation (cpm x 10<sup>-3</sup>)



**FIG. 14C**

(<sup>3</sup>H)-Thymidine incorporation (cpm x 10<sup>-3</sup>)



**FIG. 14D**




FIG. 15A







FIG. 15B




**FIG. 16A**




**FIG. 16B**




**FIG. 17A**




**FIG. 17B**




**FIG. 18A**




**FIG. 18B**




**FIG. 19A**




**FIG. 19B**




**FIG. 19C**



**FIG. 20A**



**FIG. 20B**



**FIG. 20C**






FIG. 21




Figure 22







Figure 23



→ B7.1



→ B7.2



→ CD40

Figure 24

The graph displays two data series: one for a group with 100% mortality (represented by open circles) and another for a group with 100% survival (represented by open triangles). The Y-axis represents the 'Mean Clinical Score' ranging from 0 to 4, and the X-axis represents 'Days Post Induction' ranging from 0 to 120. The 100% mortality group shows a rapid decline in clinical score, starting around 2.5 at day 20 and reaching near zero by day 40. The 100% survival group shows a more gradual decline, starting around 3.5 at day 20 and reaching near zero by day 120.

FIGURE 25




FIGURE 26A




FIGURE 26B

104090-1064860




FIGURE 27

2000-10-26 10:26:00




Figure 28



FIGURE 29




FIGURE 29

T04090-10662960




Figure 30




Figure 31




Figure 32




Figure 33




Figure 34




Figure 35




Figure 36






Figure 37






Figure 38




Figure 39




Figure 40




Figure 41